Blood Test Reads Tiny RNAs to Tell Brain Tumors Apart Without Surgery

Diagnosing a brain tumor has long meant the same unwelcome sequence: symptoms appear, an MRI reveals something suspicious, and a neurosurgeon threads a needle deep into the brain to extract a biopsy. That tissue sample remains the gold standard, but it carries real risks, takes time to arrange, and often arrives only after the disease has already declared itself. Now a team at the National Medical Research Centre for Oncology in Rostov-on-Don, Russia, reports a different path. In a study published in the Journal of Neuro-Oncology, the researchers show that a simple tube of blood plasma, read through the lens of ten circulating microRNAs, can distinguish between several of the most common brain tumors — glioblastoma, astrocytoma, oligodendroglioma, meningioma, and brain metastases from lung and breast cancer — without ever touching the skull.

MicroRNAs, or miRNAs, are short strands of RNA, roughly twenty to twenty-four nucleotides long, that never get translated into proteins. Instead they act as molecular throttles: each miRNA can bind to messenger RNA transcripts and suppress their translation or mark them for destruction. A single miRNA family can regulate hundreds of different target genes, which is why these tiny molecules sit at the junction of nearly every cellular process, from proliferation to apoptosis. Tumors exploit this system. As cancer cells grow, die, and remodel their surroundings, they release miRNAs into the bloodstream, often packaged inside small extracellular vesicles or bound to protective protein complexes. Those circulating molecules survive the journey intact, and their abundance shifts in patterns that reflect what is happening inside the tumor.

The Rostov-on-Don team, led by Dmitry Yu. Gvaldin and including Natalia A. Petrusenko, Ekaterina P. Omelchuk, Moez Eid, Dema Alset, and Oleg I. Kit, set out to test whether those patterns are specific enough to be clinically useful. They enrolled 178 patients: 67 with glioblastoma, 33 with astrocytoma, 6 with oligodendroglioma, 33 with meningioma, 14 with brain metastases from lung cancer, and 25 with brain metastases from breast cancer. From each participant they drew blood, isolated the circulating miRNAs from the plasma, and quantified the expression of a targeted panel of miRNAs alongside reference genes using reverse transcription quantitative polymerase chain reaction, or RT-qPCR. This technique converts RNA into complementary DNA and then amplifies it cycle by cycle, so that the number of amplification rounds needed to detect a signal becomes a precise measure of how abundant each miRNA was in the original sample.

Raw qPCR data, however, are notoriously sensitive to technical noise — variation in extraction efficiency, reverse transcription, and plate effects can all masquerade as biology. The researchers applied established normalization strategies to correct for this, a step that prior work has shown is essential for circulating miRNA studies to be reproducible. With clean expression data in hand, they turned to bioinformatics. Using computational tools for building diagnostic models, they constructed classifiers that take the expression levels of just ten miRNAs as input and output a prediction of which tumor type the blood sample came from. Crucially, they validated these models, meaning the models were tested for their ability to distinguish tumor types rather than merely fitted to the data they were trained on.

The scope of the comparison is what sets the study apart. Most previous circulating miRNA studies in neuro-oncology have focused on a single question — glioblastoma versus healthy controls, or glioma versus a single metastasis type. This work, the authors note, is among the first to include three types of malignant primary brain tumors alongside a benign tumor, meningioma, and two distinct types of secondary brain tumors in one diagnostic framework. That breadth matters clinically. A patient who presents with a brain lesion and a history of lung cancer faces a fundamentally different treatment path than one whose lesion turns out to be a slow-growing astrocytoma, yet distinguishing these entities currently requires tissue. A blood-based panel that could narrow the differential before surgery would change the conversation between neurosurgeon and patient.

Beyond the diagnostic models themselves, the team asked a deeper biological question: what are these miRNAs actually doing? They mapped the miRNAs to their experimentally validated target genes and performed functional enrichment analysis using three curated pathway databases — KEGG, Reactome, and WikiPathways — which catalogue known signaling networks and cellular processes. The analysis converged on twelve genes that emerged as the most significant targets: CASP3, EIF2S2, FYN, GNAQ, ITPR1, KPNB1, KREMEN1, MTOR, SREBF1, TYMS, VPS4B, and WASL. The list reads like a cross-section of tumor biology. CASP3 encodes caspase-3, the executioner enzyme of programmed cell death. MTOR is the central regulator of cell growth and metabolism, a pathway already targeted by cancer drugs. TYMS, thymidylate synthase, is the direct target of chemotherapy agents like 5-fluorouracil. ITPR1, an intracellular calcium release channel, has previously been implicated as a hub gene in medulloblastoma and, in recent work, in driving glioblastoma progression through mitochondrial dynamics.

That the miRNA signatures point toward these pathways is more than a technical footnote. It suggests the circulating miRNAs are not random debris shed from dying cells but a functional readout of the molecular machinery each tumor depends on. A glioblastoma, with its aggressive MTOR-driven growth, should release a different miRNA cocktail than a meningioma, which grows slowly and rarely invades. The enrichment analysis provides a mechanistic plausibility check on the diagnostic models: the classifiers are not just memorizing patterns but tracking biology that makes sense given what is known about these diseases.

The clinical implications run in two directions. First, early detection. Brain tumors are typically diagnosed only after symptoms force a patient to seek care, and those symptoms — headaches, seizures, cognitive changes — often appear late. A minimally invasive blood test could, in principle, be deployed in patients at risk or in those with incidental imaging findings, flagging malignancy before a lesion becomes large enough to cause neurological damage. Second, monitoring. Patients with glioblastoma face recurrence almost universally, and current surveillance relies on serial MRI, which struggles to distinguish true progression from treatment-related changes such as pseudoprogression. A plasma miRNA panel could be repeated at every follow-up visit, offering a molecular signal of recurrence that complements what radiologists see on scans. The same logic applies to metastatic disease, where distinguishing breast cancer from lung cancer metastases in the brain can guide which systemic therapy to deploy.

None of this means the biopsy is obsolete. The study’s own limitations are worth stating plainly: the oligodendroglioma cohort contained only six patients, a small number that limits statistical confidence for that tumor type; the data supporting the findings are restricted due to legal and privacy constraints, which complicates independent verification; and, as with any diagnostic model, performance in a retrospective cohort does not guarantee performance in the messy, comorbidity-laden reality of a clinic. External validation in larger, multi-center, prospective cohorts will be the decisive test. The field of liquid biopsy has seen many promising biomarker panels stall at exactly this stage, unable to reproduce their early accuracy when moved to new populations and different laboratory platforms.

Still, the trajectory of the work is compelling. The study was conducted as part of a state-funded program explicitly aimed at developing a minimally invasive diagnostic panel for brain tumors based on plasma circulating miRNAs, and the authors frame their results as a foundation for early detection and recurrence monitoring of both primary and metastatic brain lesions. If subsequent validation holds up, the ten-miRNA panel could become a routine complement to imaging — a blood draw ordered alongside the MRI, giving oncologists a molecular fingerprint of the tumor weeks or months before a needle would ever need to enter the brain. For patients facing the most feared diagnosis in medicine, that would represent a genuine shift: from reacting to symptoms toward reading the tumor’s own molecular whispers in a vial of blood.

Subject of Research: A circulating miRNA blood test for minimally invasive differential diagnosis of primary and metastatic brain tumors

Article Title: A novel minimally invasive diagnostic approach of various brain malignancies based on differential miRNA expression

Article References: A novel minimally invasive diagnostic approach of various brain malignancies based on differential miRNA expression. (n.d.). https://doi.org/10.1007/s11060-026-05810-1

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05810-1

Keywords: miRNA, liquid biopsy, brain tumors, glioblastoma, astrocytoma, meningioma, brain metastases, RT-qPCR, plasma biomarkers, diagnostic models, MTOR, neuro-oncology